VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study

VBI Vaccines announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation hepatitis B vaccine. More than 1,600 adults have now been enrolled in the PROTECT study at 27 sites across the U.S., Europe, and Canada. 

Click here to read the full release